VENUSS prognostic model for papillary kidney cancer
A recent study published in BMC Medicine this month investigates [...]
ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance
Results from the latest adjuvant study with a vascular endothelial [...]
A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy
An American company called Genomic Health has been collaborating with [...]
16-gene recurrence score for high-risk kidney cancer offers prognostic value
Results from a phase III trial presented at the American [...]
